Effects of Isoflavonoid and Vitamin D Synergism on Bone Mineral Density-A Systematic and Critical Review

Overview

Journal Nutrients

Date 2023 Dec 23

PMID 38140273

Authors

Milosz Miedziaszczyk

Adam Maciejewski

Ilona Idasiak-Piechocka

Marek Karczewski

Katarzyna Lacka

Affiliations

Soon will be listed here.

Abstract

Phytoestrogens are non-steroidal plant compounds, which bind to α and β estrogen receptors, thereby causing specific effects. The best-known group of phytoestrogens are flavonoids, including isoflavonoids-genistein and daidzein. They play a role in the metabolism of bone tissue, improving its density and preventing bone loss, which contributes to reducing the risk of fractures. Vitamin D is found in the form of cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) and is traditionally recognized as a regulator of bone metabolism. The aim of this review was to evaluate the synergistic effect of isoflavonoids and vitamin D on bone mineral density (BMD). The MEDLINE (PubMed), Scopus and Cochrane databases were searched independently by two authors. The search strategy included controlled vocabulary and keywords. Reference publications did not provide consistent data regarding the synergistic effect of isoflavonoids on BMD. Some studies demonstrated a positive synergistic effect of these compounds, whereas in others, the authors did not observe any significant differences. Therefore, further research on the synergism of isoflavonoids and vitamin D may contribute to a significant progress in the prevention and treatment of osteoporosis.

References

Hwang C, Kwak H, Lim H, Lee S, Kang Y, Choe T . Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006; 101(4-5):246-53. DOI: 10.1016/j.jsbmb.2006.06.020. View

Burt L, Billington E, Rose M, Raymond D, Hanley D, Boyd S . Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA. 2019; 322(8):736-745. PMC: 6714464. DOI: 10.1001/jama.2019.11889. View

Locantore P, Del Gatto V, Gelli S, Paragliola R, Pontecorvi A . The Interplay between Immune System and Microbiota in Osteoporosis. Mediators Inflamm. 2020; 2020:3686749. PMC: 7061131. DOI: 10.1155/2020/3686749. View

Kuchuk N, van Schoor N, Pluijm S, Chines A, Lips P . Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res. 2008; 24(4):693-701. DOI: 10.1359/jbmr.081209. View

Farhan H, Wahala K, Cross H . Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol. 2003; 84(4):423-9. DOI: 10.1016/s0960-0760(03)00063-3. View

Jiang L, Zhang C, Zhang Y, Ma F, Guan Y . Associations between polymorphisms in gene and the risk of osteoporosis: a meta-analysis. Arch Physiol Biochem. 2020; 128(6):1637-1644. DOI: 10.1080/13813455.2020.1787457. View

DeLoughery E, Dow M . Decreased bone mineral density and reproductive axis dysfunction: more than oestrogen. Neth J Med. 2020; 78(2):50-54. View

Siddiqui J, Partridge N . Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. Physiology (Bethesda). 2016; 31(3):233-45. PMC: 6734079. DOI: 10.1152/physiol.00061.2014. View

Santos-Martinez N, Diaz L, Ortiz-Ortega V, Ordaz-Rosado D, Prado-Garcia H, Avila E . Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells. Am J Cancer Res. 2022; 11(12):5951-5964. PMC: 8727803. View

10.

Bischoff-Ferrari H, Willett W, Wong J, Stuck A, Staehelin H, Orav E . Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169(6):551-61. DOI: 10.1001/archinternmed.2008.600. View

11.

Mori G, DAmelio P, Faccio R, Brunetti G . The Interplay between the bone and the immune system. Clin Dev Immunol. 2013; 2013:720504. PMC: 3725924. DOI: 10.1155/2013/720504. View

12.

Bikle D . Vitamin D and bone. Curr Osteoporos Rep. 2012; 10(2):151-9. PMC: 3688475. DOI: 10.1007/s11914-012-0098-z. View

13.

Ushiroyama T, Okamura S, Ikeda A, Ueki M . Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss. Int J Gynaecol Obstet. 1995; 48(3):283-8. DOI: 10.1016/0020-7292(94)02280-c. View

14.

Akhlaghi M, Ghasemi Nasab M, Riasatian M, Sadeghi F . Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2019; 60(14):2327-2341. DOI: 10.1080/10408398.2019.1635078. View

15.

Park C, Weaver C . Vitamin D interactions with soy isoflavones on bone after menopause: a review. Nutrients. 2012; 4(11):1610-21. PMC: 3509509. DOI: 10.3390/nu4111610. View

16.

Yi X, Wang Z, Wang Y . Genistein for glycolipid metabolism in postmenopausal women: a meta-analysis. Climacteric. 2021; 24(3):267-274. DOI: 10.1080/13697137.2020.1859473. View

17.

Lu L, Chen N, Nayeem F, Ramanujam V, Kuo Y, Brunder D . Novel effects of phytoestrogenic soy isoflavones on serum calcium and chloride in premenopausal women: A 2-year double-blind, randomized, placebo-controlled study. Clin Nutr. 2017; 37(6 Pt A):1862-1870. PMC: 5948121. DOI: 10.1016/j.clnu.2017.11.002. View

18.

Bingham S, Atkinson C, Liggins J, Bluck L, Coward A . Phyto-oestrogens: where are we now?. Br J Nutr. 1998; 79(5):393-406. DOI: 10.1079/bjn19980068. View

19.

Marini H, Bitto A, Altavilla D, Burnett B, Polito F, Di Stefano V . Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab. 2008; 93(12):4787-96. DOI: 10.1210/jc.2008-1087. View

20.

Sahin N, Balci T, Kucuk O, Smith M, Sahin K . Effects of 25-hydroxycholecalciferol and soy isoflavones supplementation on bone mineralisation of quail. Br Poult Sci. 2009; 50(6):709-15. DOI: 10.1080/00071660903261944. View